Clinical trials: Neuroendocrine Tumor Metastatic
Malignant Head and Neck Neoplasm, Malignant Neoplasm
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
The main goal of this phase of the study is to determine if objectively assessed Physical Activity (PA) levels in advanced-cancer patients are associated with health care provider (HCP)-assessed ECOG performance status and…
- Conditions
- Malignant Head and Neck Neoplasm, Malignant Neoplasm, Metastatic Malignant Neoplasm in the Neck, Metastatic Malignant Neoplasm in the Uterine Cervix
- Trial name
- NCT01365169
- Testing
- Exercise Intervention, Health Telemonitoring, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 590 people
- Sponsor
- M.D. Anderson Cancer Center
Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
This phase I trial is studying the side effects and best dose of alvespimycin hydrochloride in treating patients with metastatic or unresectable solid tumors.
- Conditions
- Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Breast Cancer
- Trial name
- NCT00089362
- Testing
- alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Colon Cancer
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
This pilot clinical trial studies copper Cu 64 anti-carcinoembryonic antigen (CEA) monoclonal antibody M5A positron emission tomography (PET) in diagnosing patients with CEA positive cancer.
- Conditions
- Breast Cancer, Colon Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT02293954
- Testing
- radionuclide imaging, positron emission tomography, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Carcinoid Tumor
A Study of Axitinib in Advanced Carcinoid Tumors
The main purpose of this study is to see whether Axitinib will help prolong the time that the patient's carcinoid tumors remain stable, and to examine their treatment response through testing.
- Trial name
- NCT01435122
- Testing
- Axitinib
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma (Skin)
Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells.
- Trial name
- NCT00003027
- Testing
- aldesleukin, filgrastim, recombinant interferon alfa
- Where
- 94 sites in United States
- Volunteers
- 482 people
- Sponsor
- Eastern Cooperative Oncology Group
Metastatic Melanoma
TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma
This is an open-label, phase 1 trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with lymphocyte-depleting chemotherapy and TILs in metastatic melanoma patients.
- Trial name
- TUNINTIL-2 (NCT06961786)
- Testing
- TILT-123, TIL, Cyclophosphamide
- Where
- Denmark
- Volunteers
- 9 people
- Sponsor
- TILT Biotherapeutics Ltd.
Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 in participants with neurotensin receptor 1…
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT05605522
- Testing
- [225]-FPI-2059, [111In]-FPI-2058
- Where
- 8 sites in United States, Australia
- Volunteers
- 19 people
- Sponsor
- 3B Pharmaceuticals GmbH
Metastatic Melanoma, Skin Cancer
Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma
Background: Melanoma antigen recognized by T-cells (MART)-1 is a protein present in melanoma cells. An experimental procedure developed for treating patients with melanoma uses the anti-MART-1 F5 gene and a type of virus to make…
- Trial name
- NCT00612222
- Testing
- autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes, ALVAC MART-1 Vaccine, aldesleukin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma
A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma
Obatoclax Mesylate (GMX1777) is a water-soluble, intravenously-administered pro-drug of GMX1778. GMX1777 is rapidly converted to GMX1778 in vivo.
- Trial name
- NCT00724841
- Testing
- Obatoclax Mesylate, Temozolomide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Gemin X
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
The purpose of this study is to evaluate the safety and activity of BPX-701 in participants with relapsed AML, previously treated MDS, or metastatic uveal melanoma expressing high levels of PReferentially expressed Antigen in…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Uveal Melanoma
- Trial name
- NCT02743611
- Testing
- BPX-701, Rimiducid
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Bellicum Pharmaceuticals
Malignant Melanoma
Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma
This is an open-label, multi-center, clinical phase II study to explore the correlation of the genetic make-up of the treated tumor before start of therapy and to correlate clinical response at 8 weeks as well as metabolic…
- Trial name
- BOTTOM (NCT02410863)
- Testing
- Dabrafenib, Trametinib
- Where
- 6 sites in Germany
- Volunteers
- 10 people
- Sponsor
- Prof. Dr. med. Dirk Schadendorf
Recurrent Melanoma, Stage IV Melanoma
Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma
This phase I trial studies the side effects and best dose of autologous T-antigen-presenting cells (T-APC) vaccine following therapeutic autologous lymphocytes (CTL) and cyclophosphamide in treating patients with metastatic…
- Trial name
- NCT01339663
- Testing
- cyclophosphamide, aldesleukin, autologous tumor cell vaccine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Fred Hutchinson Cancer Center
Melanoma
STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma
STA9090 is a drug which inactivates or blocks the work of a protein called Heat Shock Protein 90 or HSP90. HSP90 is a protein that helps some molecules inside your cells to have the right shape.
- Trial name
- NCT01551693
- Testing
- STA-9090
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Dana-Farber Cancer Institute
Cutaneous Melanoma
Neoadjuvant Atezolizumab in Cutaneous Melanoma
The purpose of this research study is to see whether using atezolizumab before surgery is safe and does not cause side effects that delay surgery in participants with cutaneous melanoma that has not spread to other areas of the…
- Trial name
- NCT04020809
- Testing
- Atezolizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Methodist Hospital Research Institute
Kidney Cancer, Melanoma (Skin)
Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases
RATIONALE: Cryoablation kills cancer cells by freezing them. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells.
- Conditions
- Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Pain
- Trial name
- NCT00540969
- Testing
- cryosurgery, radiation therapy
- Where
- 7 sites in United States
- Volunteers
- 3 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Neuroendocrine Tumors, Metastases, Neoplasm
High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
The goal of this clinical research study is to learn if I-131 Metaiodobenzylguanidine (MIBG) can shrink or slow the growth of the tumor(s) in patients with metastatic neuroendocrine tumors.
- Trial name
- NCT00037869
- Testing
- I-131 Metaiodobenzylguanidine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Solid Tumor, Colorectal Cancer
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors.
- Conditions
- Metastatic Solid Tumor, Colorectal Cancer, Neuroendocrine Tumors, Small Cell Lung Cancer
- Trial name
- NCT04579757
- Testing
- Surufatinib and Tislelizumab _ Part 1, Surufatinib and Tislelizumab _ Part 2
- Where
- 18 sites in United States
- Volunteers
- 87 people
- Sponsor
- Hutchmed
Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma
Aerosolized Aldesleukin in Treating Patients With Lung Metastases
This phase I/II trial studies the side effects and best dose of aerosolized aldesleukin and to see how well it works in treating patients with cancer that has spread from the original tumor to the lungs.
- Conditions
- Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Metastatic Osteosarcoma, Metastatic Renal Cell Cancer
- Trial name
- NCT01590069
- Testing
- Aerosolized Aldesleukin, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center
Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
This phase II clinical trial studies how well thermal ablation and spine stereotactic radiosurgery work in treating patients with cancer that has spread to the spine (spine metastases) and is at risk for compressing the spinal…
- Conditions
- Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine
- Trial name
- NCT02713269
- Testing
- Computed Tomography, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Melanoma
Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma
A phase I-II study of treatment of metastatic melanoma using induction therapy with Biochemotherapy plus Bevacizumab followed by consolidation therapy with Ipilimumab (BBI).
- Trial name
- BBI (NCT01743157)
- Testing
- Biochemo + bevacizumab then ipilimumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- California Pacific Medical Center Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.